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AbsTrACT
Objective Clear information is essential to properly 
determine preference in medical intervention. In 
neovascular age-related macular degeneration, patients 
need to understand the balance of risk and benefit of 
anti-vascular endothelial growth factor (VEGF) treatment. 
This balance is altered by the number of injections 
administered.
Methods Natural frequencies, displayed as 
pictographically as icon arrays, are used to show material 
outcomes from the MARINA and HARBOR (12 months) 
trials. We also calculated the number needed to treat (NNT) 
and number needed to harm (NNH).
results MARINA 24-month data show the absolute 
risk reduction is 37% and the NNT is 3; meaning for one 
patient to benefit three need to be treated.
12 months’ HARBOR data show that compared with as-
needed treatment, scheduled monthly injection treatment 
increases the number of patients achieving a better visual 
outcome. The number of patients suffering harm is also 
increased by the additional injections.
Conclusion Displaying MARINA and HARBOR trial data 
as natural frequencies, with numbers needed to treat and 
harm, communicates complimentary information on the 
positive and negative aspects of anti-VEGF treatment.
InTrOduCTIOn
Neovascular age-related macular degenera-
tion (nv-AMD) or wet AMD can be considered 
as an acute exacerbation of an underlying 
chronic disease state: dry AMD. nv-AMD 
affects only 10% of all AMD sufferers but is 
disproportionately disabling. Vision is lost as 
a result of abnormal, leaky blood vessel devel-
opment, which damages the macula.
Bevacizumab (Avastin), ranibizumab 
(Lucentis) and aflibercept (Eylea) are 
available treatment options, delivered as 
intravitreal injections. These drugs block 
vascular endothelial growth factor (VEGF) 
and stop the new blood vessel from growing 
and leaking, but do not benefit the underlying 
dry AMD. The National Institute for Health 
and Care Excellence website features ranibi-
zumab (Lucentis) in AMD pharmacological 
treatments,1 with the comment that there 
are ‘…no clinically significant differences 
in effectiveness and safety is between the 
different anti-VEGF treatments.’ For this 
reason, we confine our consideration of risks 
and benefits to ranibizumab (Lucentis).
Accessible information on the risks and 
benefits may be confusing for patients consid-
ering anti-VEGF treatment, possibly due to 
the way the information entered the public 
domain. The New York Times first reported 
successful treatment for nv-AMD with anti-
VEGF on 19 July 2005; ‘Genentech Says 
Drug Restores Vision,’2 the report detailed 
‘Lucentis restored patients' vision …(with) …
an average gain of seven letters …compared 
with a 10.5-letter loss for …placebo.’ Ranibi-
zumab (Lucentis) was not commercially 
available at that time but ophthalmologists in 
the USA and the UK had already begun using 
bevacizumab (Avastin—ranibizumab’s parent 
molecule) ‘off-label’3 to treat nv-AMD from 
about 2005.
Key messages
What is already known about this subject?
 ► Intravitreal anti-vascular endothelial growth factor is 
an effective treatment for neovascular age-related 
macular degeneration.
What are the new findings?
 ► Restating landmark publications as natural frequen-
cies enhances appreciation of the balance of risks 
and benefits; specifically that although more injec-
tions provide better visual outcomes, risk also in-
creases. The risks may well come to exceed benefit 
earlier than is currently appreciated.
How might these results change the focus of 
research or clinical practice?
 ► Authors of these and other publications should con-
sider reviewing their data to more precisely delin-
eate the balance of risk and benefit.
 ► The Montgomery decision says, the ‘doctor is under 
a duty to inform the patient of the material risks in-
herent in the treatment,’ any change in the balance 
of risk and benefit with repeated injections is materi-
al and patients need to understand if, how and when 
this balance changes.
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Food and Drug Administration (FDA) approval and 
commercial availability of Lucentis followed the FDA’s 
June 2006 press release.4 ‘The FDA Approves New 
Biologic Treatment for Wet Age-Related Macular Degen-
eration’—which explained:
 ► Lucentis (ranibizumab) is the first treatment which, 
when given as a dose each month, can maintain the 
vision of more than 90% of patients with nv-AMD.
 ► Ninety-five per cent of patients who received a 
monthly injection maintained their vision compared 
with 60% of control patients.
 ► One-third of patients had improved vision after 12 
months.
 ► After 24 months, these findings were maintained with 
continued monthly doses of Lucentis.
 ► Serious adverse events were rare and related to the 
injection procedure, for example, inflammation, 
retinal detachment and cataracts.
This and other media announcements meant that 
many became aware of the benefits of ranibizumab 
(Lucentis) treatment more than a year before the 
evidence for these assertions was available for scrutiny. 
The MARINA randomised controlled trial was published 
on 5 October 2006 and supported claims for the bene-
fits of ranibizumab (Lucentis). These notions seem now 
to have entered the collective unconscious and have 
become unchallengeable.
The level of evidence MARINA provided, and this 
remains the only treatment –v- no treatment study of 
anti-VEGFs, ought to have made a 24 injection in 2 years 
treatment schedule the norm - as was the case in the later 
HARBOUR study.5
However, this ran contrary to the experience of Avastin 
early adopters who knew that only two to four injections of 
Avastin were needed to produce a worthwhile outcome.6 
Also, the 2009 PrONTO study7 showed ‘variable-dosing 
regimen with intravitreal Ranibizumab (Lucentis) resulted in 
VA outcomes comparable with the outcomes from… MARINA…, 
but fewer intravitreal injections were required.’
In real-world practice, a PrONTO-like ‘treat and extend’ 
regimen has become familiar, patients currently receive a 
mean of 5.0 and 2.2 ranibizumab (Lucentis) injections in 
the first and second year, respectively,8 considerably less 
than MARINA’s 24 injections, in 2 years of treatment.
Ranibizumab (Lucentis) treatment also exposes 
patients to risk of harms to their eyes and general 
health. The Montgomery decision of the Supreme 
Court9 in 2015 set out, ‘The correct position, in relation to 
the risks of injury involved in treatment…. An adult person 
of sound mind is entitled to decide which, if any, of the avail-
able forms of treatment to undergo, and her consent must be 
obtained before treatment interfering with her bodily integrity 
is undertaken.’ The judgement continues, (the) ‘doctor is 
under a duty to inform the patient of the material risks inherent 
in the treatment. A risk was material, for these purposes, if a 
reasonably prudent patient in the situation of the patient would 
think it significant.’ The decision quotes directly from the 
General Medical Council’s Good Medical Practice,10 ‘Give 
patients the information they want or need in a way they can 
understand.’
In the management of nv-AMD, anti-VEGF injection 
is a decision for the patient to make. This obliges the 
ophthalmologists to share with their patients material 
information that is comprehensible. This information 
derives from clinical trials, reliant on properly collected 
data, which are then statistically analysed and presented 
in scientific journals. This can be a barrier to under-
standing for those who do not have the high statistical 
literacy. Gigerenzer11 has shown how even expressing 
results as percentages can produce a math’s puzzle that 
will cloud the minds of many people, including health 
professionals, who then may inadvertently impart 
misleading advice to their patients.
Natural frequencies are a joint frequency of two events,12 
such as the number of patients with disease who respond 
to treatment or no treatment. Using natural frequencies 
is an alternative to presenting the same information as 
statistically analysed means, distribution intervals and 
percentages. Presenting material information using 
natural frequencies graphically can overcome many of 
the cognitive biases that inhibit accurate consideration of 
statistical information.13 Herein, we explain how we used 
data from MARINA and HARBOR to produce icon arrays 
to provide patients with information on the benefits of 
ranibizumab (Lucentis) treatment, the inherent risks 
and their magnitudes.
MATerIAls And MeTHOds
We reviewed the MARINA and HARBOR studies. The 
MARINA study was used as it provides guidance on 
whether a patient should choose to accept treatment with 
anti-VEGF for nv-AMD, and HARBOR because it provides 
information that can guide on how many injections a 
patient should choose to accept.
From each study’s results section relevant outcome 
data were entered into prerelease Factarray software.
The Factarray app is a decision aid for consent. It is 
designed to ensure that both the physician and the 
patient share the same understanding of the risks and 
benefit inherent in any intervention; in this instance, 
nv-AMD treatment with anti-VEGF. The clinician can 
input data into the software using the highest available 
level of evidence on any intervention. The app will 
generate a list of facts on the intervention, a pictographic 
icon array allowing comparison of outcomes in the situa-
tion under consideration, for example, treatment versus 
no treatment; also basic data, number of patients needed 
to treat to produce each harm or benefit.
Each colour-coded dot in the icon array represents the 
experience 1 out of 1000 similar patients.
resulTs
The MARINA study, at 24 months, showed that 90% of 
those treated with monthly Lucentis 0.5 mg achieved the 
primary or secondary outcome measure, by either losing 
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Figure 1 MARINA 24-month data; each dot on this icon 
array represents the experience of each one of a thousand 
patients. Benefits are coloured green, death is coloured 
black, harms are coloured red (when the frequency of an 
event—in this case visual benefit—exceeds 50% of subjects, 
the colour surrounds the dot rather than fills it). CVA, 
cerebrovascular accident; MI, myocardial infarction.
Figure 2 HARBOR 12-month data; each dot on this icon 
array represents the experience of each one of a thousand 
patients. Benefits are coloured green, death is coloured 
black, harms are coloured red (when the frequency of an 
event—in this case visual benefit—exceeds 50% of subjects, 
the colour surrounds the dot rather than fills it). CVA, 
cerebrovascular accident; MI, myocardial infarction.
fewer than or gaining 15 Early Treatment Diabetic Reti-
nopathy Study letters (figure 1).
The absolute risk reduction (ARR) is the difference the 
treatment makes and is the difference between that 90% 
and the 52.9% of untreated subjects who achieved the 
same result: in this case 37%.
The reciprocal gives the number needed to treat 
(NNT)–3, meaning, for every three people treated with 
24 Lucentis injections one person will achieve the trial 
benefit.
The harms are higher in the treated group: 1 in 26 of 
this group died compared with 1 in 40 controls, 1 in 29 
suffered an ocular adverse event compared with 1 in 83 
controls, 1 in 58 suffered a stroke compared with 1 in 125 
controls.
The HARBOR study evaluated the efficacy and safety 
of intravitreal ranibizumab (Lucentis) 0.5 and 2.0 mg 
administered monthly and on an as-needed (PRN, pro 
re nata) basis in treatment-naïve patients with subfo-
veal nv-AMD (wet AMD). The study confirmed 0.5 mg 
as the optimum ranibizumab (Lucentis) dose. Because 
patients could ‘crossover’ after 12 months’ efficacy and 
safety information is only valid up to 12 months. These 
12-month data allow comparison of benefits and harms 
between those who underwent 12 scheduled monthly 
injections compared with PRN patients who had a total 
of six injections in the first 12 months after diagnosis.
From HARBOR at 12 months: the ARR was 3.3%. This 
being the greater percentage of those subjects treated 
with 12 ranibizumab (Lucentis) 0.5 mg injections who 
achieved the primary or secondary outcome measure 
by either losing fewer than or gaining 15 EDTRS letters 
(figure 2) than those treated with six injections. The 
reciprocal is the NNT of 30. This means 30 patients need 
to be treated with monthly rather than PRN injections for 
one such patient to benefit.
The additional harms per thousand for the six addi-
tional injections in the first 12 months of the study are: 
14 deaths, 15 heart failures, 3 strokes, 7 endophthalmitis 
and 15 myocardial infarctions.
dIsCussIOn
The form in which the authors of the MARINA and 
HARBOR originally presented information caused diffi-
culties. MARINA reported relative risk reduction but 
reported neither ARR nor the NNT. This is contrary to 
clause 7 of the Association of the British Pharmaceu-
tical Industry Code of Practice14 that mandates outcome 
expressed as ARR and NNT and says: ‘Referring only to rela-
tive risk, especially with regard to risk reduction, can make a 
medicine appear more effective than it actually is. In order to 
assess the clinical impact of an outcome, the reader also needs 
to know the absolute risk involved. In that regard relative risk 
should never be referred to without also referring to the absolute 
risk.’
There are other potential sources of confusion. 
MARINA commented on the benefit of only the first 
injection, ‘the mean improvement from baseline in visual 
acuity scores was evident 7 days after the first injection.’
MARINA did not discuss the relative benefits or the 
harms experienced after each of any of the remaining 
23 injections. This may have invited an assumption; 
that repeated injections are essential to maintain visual 
improvement and that this imperative outweighs the 
inherent risk of repeating treatment.
MARINA did not publish the absolute number of 
letters read and only the change in the number of letters 
read since baseline. The AURA10 observational study did, 
saying, ‘Visual acuity: change from baseline… an improve-
ment in (mean) visual acuity was observed until about 
day 120 thereafter visual acuity noticeably decreased.’10 
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This seems to suggest the response of nv-AMD to anti-
VEGF treatment may be greatest during the early stages 
of the disease.
When the New York Times reported first on AMD treat-
ment, ‘Laser use reported effective in averting Blindness 
in The Elderly,’15 they emphasised the short window of 
opportunity for treatment to be effective, ‘The results are 
so promising that The NEI…(The USA National Eye Institute—
the trial’s sponsors)… took the unusual step of disclosing them 
at a news conference to spread the word quickly. It has also termi-
nated further clinical tests and today urged all potential patients 
to seek laser treatment promptly… The results demonstrated that 
early treatment was essential. Of the cases in which diagnosis 
was made within two weeks of the onset of symptoms, 83 percent 
were still treatable. In contrast, only 10 percent could be treated if 
five to six months had elapsed.
It seems difficult to reconcile the idea of laser treat-
ments being most effective in the early months of 
nv-AMD’s natural history with MARINA’s conclusion that 
‘Lucentis treatment is needed for two years.’
Genentech’s current ‘Lucentis’ data sheet16 may 
reinforce this notion, ‘LUCENTIS 0.5 mg (0.05 mL) is 
recommended to be administered by intravitreal injection once a 
month (approximately 28 days).
Although not as effective, patients may be treated with three 
monthly doses followed by less frequent dosing with regular 
assessment. Although not as effective, patients may also be 
treated with one dose every 3 months after four monthly doses. 
Patients should be assessed regularly.’
‘Although not as effective’ suggests to us that patients 
may be disadvantaged by not having enough treatments, 
but this statement is not balanced by considering the 
possible harms of additional treatment.
The IVAN14 study—comparing safety and efficacy of 
Lucentis to Avastin—reports a similar level of serious harm 
at about 4%–7% of patients. The HARBOR8 study found 
2.6%–3.6% risk of serious harm to the eyes, with serious 
harm to general health developing in about 4% of those 
treated with Lucentis. Our presentation of HARBOR 
12-month data shows the harms are greater with more 
injections, so much so that the harms exceed the benefits 
of the six additional injections in the first year. This is 
contrary to HARBOR’s conclusion that Lucentis ‘dosed 
monthly provided optimum results in patients with wet 
AMD,’ and seems to take no account of the additional 
harms. We did not access any unpublished HARBOR data 
and so cannot assist patients in deciding the optimum 
number of injections or how long treatment ought to be 
given. We feel that perhaps our presentation ought to be 
considered alongside AURA’s observation that following 
inception of monthly treatment vision falls from day 120, 
which would be after a fifth monthly injection. This may 
be a pointer that suggests the average of nine Lucentis 
injections in total10 may be supraoptimal.
We feel expressing information as an icon array 
improves clarity on material outcomes of MARINA and 
HARBOR. The pictographs show the information in 
an unbiased and easy-to-understand17 form. Each dot 
on an icon array represents the experience of each of 
1000 patients. When an event occurs frequently (>50% 
of those studied) the indicator colour surrounds the dot 
rather than fills it. An icon array requires no mathemat-
ical training to understand and improves perception of 
likelihood in people with lower numerical aptitude.18
The impression gained from viewing the icon array is 
more representative of the likely risk and benefit than 
information from other sources.
Icon arrays improve accuracy of estimation of relative 
risk reductions when added to numerical descriptions 
without increasing perceived seriousness of risk19 
although others found icon arrays increased the percep-
tion of seriousness.20 The Factarray app allows all benefits 
and all harms to be grouped in single colour. This is 
done in figure 1 benefits in green and harms in red but 
these can be individualised in different colours to avoid 
suggesting each benefit (or harm) is of equal weight by 
using different colours for each benefit or harm—see 
figure 2.
Perception of likelihood using a 1-in-X format is assim-
ilated faster and yields higher perceived likelihoods and 
appears to be the easiest format to interpret. The effect 
of adding graphs on perceived likelihood primarily assists 
people with lower numerical aptitude.15
A key point of this communication is that the decision 
over treatment is for the patient to make, and each indi-
vidual will balance risk against benefit from their own 
perspective. When we used figure 2 as part of our consent 
process, an audit21 showed appointments for clinical 
assessment decreased by 40% and there was a 27% reduc-
tion in the number of intraocular injections given. We 
felt our patients may have chosen to forgo any benefit 
of additional anti-VEGF injections, and decided instead 
to prioritise reducing the risk of adverse events: ocular 
injury, myocardial infarction, heart failure and cerebro-
vascular accident instead.
Jawetz22 recognised four phases in the history of a drug:
1. Initial optimism causing heavy usage.
2. High-level usage.
3. Low use because of disappointment from unexpected 
consequences.
4. Finally, stabilisation at a moderate usage level.
Some 12 years since being introduced, anti-VEGF 
medication for nv-AMD seems to us to currently be 
between phases 1 and 2. Setting out the balance of risk 
and benefit more clearly in this way may help patients in 
determining their own preference for anti-VEGF treat-
ment.
We also hope to stimulate other authors to re-evaluate 
their existing trial data in order to establish the balance 
of benefit and risk; injection by injection. It may then 
be possible to use this information to allow patients to 
determine, more precisely than we have been able, 
their own optimum number of injections; where benefit 
ceases, from their perspective, to exceed risk and what 
the factors are which alter that point.
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